Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (1892)	8/25/2000 1:54:11 PM
From: scaram(o)uche	Read Replies (1) of 4974

serious cash...... Friday August 25, 1:35 pm Eastern Time Press Release SOURCE: Genencor International, Inc. Genencor's Underwriters Exercise Overallotment PALO ALTO, Calif., Aug. 25 /PRNewswire/ -- Genencor International, Inc. (Nasdaq: GCOR - news) announced today that the underwriters of its initial public offering have exercised in full their overallotment option to purchase an additional 1,050,000 shares of common stock from the company at a price of $18 per share. Net proceeds to the company from the sale of the shares of common stock are approximately $17.6 million, after deducting estimated expenses for the offering and underwriting discounts and commissions. With the exercise of the overallotment, Genencor sold a total of 8,050,000 shares of common stock through its initial public offering. The public offering was led by Merrill Lynch & Co., with Chase H&Q, Credit Suisse First Boston and Salomon Smith Barney as co-managers. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next